UBS Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $55

Benzinga Newsdesk www.benzinga.com Neutral 53.7%

Neg 0% Neu 53.7% Pos 0%

UBS analyst Ashwani Verma initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating and announces Price Target of $55.